The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 2, 2007, Pages 237-243

  Strawn, Jeffrey R ^a,b   Geracioti Jr , Thomas D ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Anxiety disorders; Anxiolytic; GAD; Panic attach; Pregabalin

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; GABAPENTIN; LORAZEPAM; PLACEBO; PREGABALIN; VENLAFAXINE;

AMBLYOPIA; ARTICLE; BODY MASS; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONCENTRATION LOSS; COORDINATION DISORDER; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FLATULENCE; GENERALIZED ANXIETY DISORDER; HUMAN; LOW DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PSYCHOMOTOR ACTIVITY; PSYCHOTHERAPY; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

EID: 34249896150     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.2.237     Document Type: Article

References (40)

1. Baetz M, Bowen RC. 1998. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry, 43:73-7.
2. Brodie MJ, Wilson EA, Wesche DL, et al. 2005. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia, 46:1407-13.
3. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther, 295:1086-1093.
4. Dooley DJ, Mieske CA, Borosky SA. 2000a. Inhibition of K+ -evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett, 280:107-110.
5. Eriksson E, Westberg P, Alling C, et al. 1991. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res, 36:243-51.
6. Fehrenbacher JC, Taylor CP, Vasko MR. 2003. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain, 105:133-41.
7. Feltner DE, Crockatt JG, Dubovsky SJ, et al. 2003. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol, 23:240-9.
8. Feng MR, Turluck D, Burleigh J, et al. 2001. Brain microdialysis and PK/ PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet, 26:123-8.
9. Field MJ, Oles RJ, Singh L. 2001. Pregabalin may represent a novel class of anxiolytic agents with abroad spectrum of activity. Br J Pharmacol, 132:1-4.
10. 2+ influx by gabapentin and pregablin in the human neocortex. Neuropharmacology, 42:229-36.
11. Furmark T, Appel L, Michelgard A, et al. 2005. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry, 58:132-42.
12. Geracioti TD Jr, Baker DG, Ekhator NN, et al. 2001. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry, 158:1227-30.
13. Geracioti TD Jr, Carpenter LL, Owens MJ et al. 2006. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry, 163:637-43.
14. Hertzberg MA, Butterfield MI, Feldman ME, et al. 1999. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry, 45:1226-9.
15. Hindmarch I, Trick L, Ridout F. 2005. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl),183:133-43.
16. Joffe RT, Swinson RP. 1987. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry, 22:1169-71.
17. Keck PE, Strawn JR, McElroy SL. 2006. Pharmacologic treatment considerations in co-occuring bipolar and anxiety disorders. J Clin Psychiatry, 67:8-15.
18. Kennedy SH, Eisfeld BS, Dickens SE, et al. 2000. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. J Clin Psychiatry, 61:276-281.
19. Kessler RC, Keller MB, Wittchen HU. 2001. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am, 24:19-39.
20. Kumar TC, Khanna S. 2000. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry, 34:527-8.
21. Lipper S, Davidson JR, Grady TA, et al. 1986. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics, 27:849-54.
22. Keck PE Jr, Taylor VE, Tugrul KC, et al. 1993. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry, 33:542-6.
23. McElroy SL, Altshuler LL, Suppes T, et al. 2004. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 outpatients with bipolar disorder. Am J Psychiatry, 158:420-6.
24. Montgomery SA, Tobias K, Zomberg GL, et al. 2006. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry, 67:771-82.
25. Olsson A, Regnell G, Traskman-Bendz L, et al. 2004. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. Eur Neuropsychopharmacol, 14:479-85.
26. Pande AC, Crockatt JG, Feltner DE, et al. 2003. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry, 160:533-40.
27. Peet M, Ali S. 1986. Propranolol and atenolol in the treatment of anxiety. Int Clin Psychopharmacol, 1:314-9.
28. Pfizer Incorporated. 2006. Package insert: pregabalin. New York, NY, USA.
29. Pohl RB, Feltner DE, Fieve RR, et al. 2005. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol, 25:151-8.
30. Primeau F, Fontaine R, Beauclair L. 1990. Valproic acid and panic disorder. Can J Psychiatry, 35:248-50.
31. Rickels K, Pollack MH, Feltner DE, et al. 2005. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry, 62:1022-30.
32. Rickels K, Schweizer E, Case WG, et al. 1990. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry, 47:899-907
33. Simon NM, Otto MW, Wisniewski SR, et al. 2004. Anxiety disorder comorbidity in bipolar patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry, 161:2222-9.
34. Stahl SM. 2004. Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry, 65:460-1.
35. Strawn JR, Geracioti TD Jr. 2007. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety, Mar 12; [Epub a head of print] PMID:17354267.
36. Tondo L, Burrai C, Scamonatti L, et al. 1989. Carbamazepine in panic disorder. Am J Psychiatry, 146:558-9.
37. Van Ameringen M, Mancini C, Pipe B, et al. 2004. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry, 65:1674-8.
38. Van Ameringen M, Mancini C, Patterson B, et al. 2006. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety, 23:1-5.
39. Woodman CL, Noyes R Jr. 1994. Panic disorder: treatment with valproate. J Clin Psychiatry, 55:134-6.
40. The World Health Organization Mental Health Survey Consortium. 2004. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA, 291:2581-90.